Biogen (BIIB -0.72%), one of the best performing big biotechs of 2013, reported solid third-quarter results today and hovered around an all-time high, but shares were up less than 1% when the market closed. In the following video, from The Motley Fool's health-care show Market Checkup, analysts Max Macaluso and David Williamson discuss the updated results from the launch of Biogen's newest multiple sclerosis drug, Tecfidera, and reasons why the company's hemophilia A drug Eloctate put a damper on today's results.